According to the TechSci Research report titled “Peripheral Blood Mononuclear Cells Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F,” the global peripheral blood mononuclear cells market was valued at USD 235.68 million in 2022 and is projected to exhibit a CAGR of 10.39% during the period 2023-2028. The growth of the Peripheral Blood Mononuclear Cells Market is primarily driven by factors such as the increased adoption of cell therapies, ongoing research and development in the field of peripheral blood mononuclear cells, and the expanding utilization of these cells in toxicology research.
Peripheral blood mononuclear cells (PBMCs) find application in exploring the impact of food bio-actives on diverse immune cells. Comprising macrophages, dendritic cells, monocytes, and lymphocytes (T cells, B cells, and NK cells), PBMCs possess a round nucleus. Nonetheless, these cells play a role in preventing the body from generating antibodies against antigens.
However, ethical and legal considerations pose a constraint. The procurement of PBMCs involves drawing blood samples from donors, thereby raising ethical and legal concerns. Obtaining donor consent, adhering to ethical guidelines, and maintaining privacy compliance are vital. Stringent regulatory frameworks and ethical considerations can restrict the collection, storage, and usage of PBMCs, potentially impeding the global peripheral blood mononuclear cells market’s growth. Additionally, the cost associated with PBMC isolation and processing remains high. Specialized equipment, reagents, and skilled personnel are prerequisites for these procedures. Furthermore, maintaining optimal storage conditions, such as low-temperature freezers, contributes to elevated costs.
The global peripheral blood mononuclear cells market is segmented based on product, application, technique, source, region, and company.
In terms of products, the market is divided into cryopreserved or frozen PBMCs, cultured or fresh PBMCs, and peripheral blood mononuclear cell isolation & viability kits. In 2022, the cryopreserved or frozen PBMCs product segment accounted for the largest revenue share, at 47.91%. These cryopreserved or frozen PBMCs, sourced from human or animal species, serve for long-term storage and can be employed in human immunology. The segment is projected to experience steady growth over the forecast period due to increasing research and development activities and improved storage facilities, contributing to its expansion within the PBMCs market.
In terms of application, the market is categorized into immunology, hematology, infectious disease, and others. The immunology segment dominated the global peripheral blood mononuclear cells market in 2022, holding a market share of 49.25%. This dominance is attributed to the upsurge in antibodies for immune system development, bolstering the market’s growth.
Regarding regional analysis, North America emerged as the dominant player in the global peripheral blood mononuclear cells market in 2022, with a revenue share of 10.90% and a CAGR of 10.90%. The region’s growth is fueled by a rising target population and an increasing number of cell therapies. Europe secured the second-largest share, with substantial growth expected in the years to come. Over the projected period, the Asia Pacific region is anticipated to exhibit robust growth.
Browse over 149 market data figures, 14 market data tables spread through 589 Pages, and an in-depth TOC on “Global Peripheral Blood Mononuclear Cells Market” – https://www.techsciresearch.com/report/peripheral-blood-mononuclear-cells-market/4561.html
The leading companies operating in the Global Peripheral Blood Mononuclear Cells Market are:
- Charles River Laboratories International, Inc.
- Lonza Group AG
- Corning Inc
- Bio-Rad Laboratories Inc
- ABCAM
- Biolegend Inc
- ZEN-Bio Inc
- DAPCEL, Inc.
- Creative Bioarray
- iXCells Biotechnologies USA, LLC
- Miltenyi Biotec B.V. & CO. KG
- STEMCELL Technologies Inc.
- Precision Medicine Group, LLC.
- StemExpress, LLC
- RayBiotech Life, Inc.
- REPROCELL Inc.
- Cytologics LLC
- BioIVT LLC
- Biopredic International
- Cell Applications, Inc.
Customers can also request for 10% free customization on this report.
“Global peripheral blood mononuclear cells market will see a robust growth during the forecast period of 2024-2028. The market for peripheral blood mononuclear cells is expected to develop due to rising research practices, cell-based therapies to either replace or regenerate human cells, tissues, or organs for normal functioning, and increased focus on regenerative medicine. Additionally, the global peripheral blood mononuclear cells market has been fueled by advancements in technology, therapies, and treatments, rising research in Biotechnology and Cell Culture Techniques, supportive government initiatives, and funding.”, said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.
“Peripheral Blood Mononuclear Cells Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028, Segmented By Product (Cryopreserved or Frozen PBMC, Cultured or Fresh PBMC, and Peripheral Blood Mononuclear Cell Isolation & Viability Kits), By Application (Immunology, Hematology, Infectious Disease, Hematology, and Others), By Techniques (Density Gradient Centrifugation, Leukapheresis, and Others), By Source (Human, Animals), By Region, Competition, Forecast and Opportunities, 2028”, has evaluated the future growth potential of Global Peripheral Blood Mononuclear Cells Market and provides statistics & information on market size, structure, and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Peripheral Blood Mononuclear Cells Market.
Key Questions Answered in This Report:
– What is the current value of the global peripheral blood mononuclear cells market, and what growth rate is anticipated during the period 2023-2028?
– How do factors like the adoption of cell therapies, ongoing research and development, and the utilization of peripheral blood mononuclear cells in toxicology research drive market growth?
– In what applications are peripheral blood mononuclear cells applied, and how do they impact immune cell study?
– What ethical and legal considerations are associated with PBMC procurement, and how can they influence the market’s growth?
– What is the significance of cryopreserved or frozen PBMCs, and how are they expected to contribute to the market’s expansion?
– How does the immunology segment dominate the peripheral blood mononuclear cells market, and what factors contribute to its growth?
– Which regions lead the global peripheral blood mononuclear cells market, and what factors propel their expansion?
– How is the Asia Pacific region expected to evolve in terms of peripheral blood mononuclear cells market growth?
Download Free Sample Report – https://www.techsciresearch.com/sample-report.aspx?cid=4561
About TechSci Research:
TechSci Research is a research-based management consulting firm providing market research and advisory solutions to its customers worldwide, spanning a range of industries. TechSci Research’s core values are value, integrity and insight. Led by a team of dynamic industry experts, TechSci Research provides its customers with high value market research and advisory services that helps them identify new market opportunities, growth engines and innovative ways to capture the market share. As a result, TechSci’s client leads rather than follow market trends. Not bound by legacy, TechSci’s cutting-edge research model leverages its decades of research knowledge and increased use of technology as engines of innovation to deliver unique research value. Provided as an alternative to traditional market research, TechSci Research reports do not just deliver data and knowledge rather highlights the insights in a more usable and interactive format for its clients.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]